Xbrane Unlocks Funds After Kicking Off Opdivo Biosimilar Trial

Developer Triggers €2m Milestone From Nivolumab Partner Intas

 
• By Dave Wallace
  
Commencing the trial has resulted in a €2m payment from Intas to Xbrane (Shutterstock)

More from Biosimilars

More from Products